These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 415443

  • 21. [Plasma and tissues distribution of misonidazole (RO 07-0582) in the rat bearing a chimio induced tumor (author's transl)].
    Akel G, Canal P, Bugat R, Soula G, Combes PF.
    J Pharmacol; 1981; 12(4):383-91. PubMed ID: 7321570
    [Abstract] [Full Text] [Related]

  • 22. The effect of misonidazole as a hypoxic radiosensitizer at low dose.
    Palcic B, Faddegon B, Skarsgard LD.
    Radiat Res; 1984 Nov; 100(2):340-7. PubMed ID: 6494445
    [Abstract] [Full Text] [Related]

  • 23. The hypoxic cell sensitizer programme in the United States.
    Phillips TL, Wasserman TH, JohnsonRJ, Gomer CJ, Lawrence GA, Levine ML, Sadee W, Penta JS, Rubin DJ.
    Br J Cancer Suppl; 1978 Jun; 3():276-80. PubMed ID: 277245
    [Abstract] [Full Text] [Related]

  • 24. Biotransformation of carbon-14-labeled muraglitazar in male mice: interspecies difference in metabolic pathways leading to unique metabolites.
    Li W, Zhang D, Wang L, Zhang H, Cheng PT, Zhang D, Everett DW, Humphreys WG.
    Drug Metab Dispos; 2006 May; 34(5):807-20. PubMed ID: 16467134
    [Abstract] [Full Text] [Related]

  • 25. Pharmacokinetic properties of antileukemic and trypanocidal compounds with amidino and imidazolinyl groups.
    Gluth WP, Busch U.
    Arzneimittelforschung; 1984 May; 34(11):1542-51. PubMed ID: 6543129
    [Abstract] [Full Text] [Related]

  • 26. Toxicology and Carcinogenesis Studies of Furosemide (CAS No. 54-31-9) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1989 May; 356():1-190. PubMed ID: 12695785
    [Abstract] [Full Text] [Related]

  • 27. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
    Coleman CN, Halsey J, Cox RS, Hirst VK, Blaschke T, Howes AE, Wasserman TH, Urtasun RC, Pajak T, Hancock S.
    Cancer Res; 1987 Jan 01; 47(1):319-22. PubMed ID: 3024818
    [Abstract] [Full Text] [Related]

  • 28. The radiosensitizer Ro 03-8799 and the concentrations which may be achieved in human tumours: a preliminary study.
    Saunders MI, Dische S, Fermont D, Bishop A, Lenox-Smith I, Allen JG, Malcolm SL.
    Br J Cancer; 1982 Nov 01; 46(5):706-10. PubMed ID: 7171452
    [Abstract] [Full Text] [Related]

  • 29. Desmethylmisonidazole (Ro 05-9963): clinical pharmacokinetics after multiple oral administration.
    Stratford MR, Minchinton AI, Dische S, Saunders MI, Anderson P.
    Int J Radiat Oncol Biol Phys; 1982 Nov 01; 8(3-4):377-9. PubMed ID: 7107355
    [Abstract] [Full Text] [Related]

  • 30. A phase I study of the hypoxic cell radiosensitizer Ro-03-8799.
    Roberts JT, Bleehen NM, Workman P, Walton MI.
    Int J Radiat Oncol Biol Phys; 1984 Sep 01; 10(9):1755-8. PubMed ID: 6480458
    [Abstract] [Full Text] [Related]

  • 31. Pharmacokinetic studies using multiple administration of RO 03-8799, a 2-nitroimidazole radiosensitizer.
    Stratford MR, Minchinton AI, Hill SA, McNally NJ, Williams MV.
    Int J Radiat Oncol Biol Phys; 1982 Sep 01; 8(3-4):469-71. PubMed ID: 7107368
    [Abstract] [Full Text] [Related]

  • 32. Cellular uptake of misonidazole and analogues with acidic or basic functions.
    Dennis MF, Stratford MR, Wardman P, Watts ME.
    Int J Radiat Biol Relat Stud Phys Chem Med; 1985 Jun 01; 47(6):629-43. PubMed ID: 3873433
    [Abstract] [Full Text] [Related]

  • 33. The concentration of desmethylmisonidazole in human tumours and in cerebrospinal fluid.
    Dische S, Saunders MI, Riley PJ, Hauck J, Bennett MH, Stratford MR, Minchinton AI.
    Br J Cancer; 1981 Mar 01; 43(3):344-9. PubMed ID: 7225285
    [Abstract] [Full Text] [Related]

  • 34. A phase I clinical study of Nimorazole as a hypoxic radiosensitizer.
    Timothy AR, Overgaard J, Overgaard M.
    Int J Radiat Oncol Biol Phys; 1984 Sep 01; 10(9):1765-8. PubMed ID: 6480460
    [Abstract] [Full Text] [Related]

  • 35. A drug for improved radiosensitization in radiotherapy.
    Dische S, Fowler JF, Saunders MI, Stratford MR, Anderson P, Minchinton AI, Lee ME.
    Br J Cancer; 1980 Jul 01; 42(1):153-5. PubMed ID: 7426325
    [No Abstract] [Full Text] [Related]

  • 36. Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice.
    Walton MI, Workman P.
    Cancer Chemother Pharmacol; 1988 Jul 01; 22(4):275-81. PubMed ID: 3168141
    [Abstract] [Full Text] [Related]

  • 37. Pharmacokinetic studies of amino acid analogues of 2-nitroimidazole, new hypoxic cell radiosensitizers.
    Agrawal KC, Larroquette CA, Garg PK.
    Int J Radiat Oncol Biol Phys; 1984 Aug 01; 10(8):1301-5. PubMed ID: 6469754
    [Abstract] [Full Text] [Related]

  • 38. Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice.
    Workman P.
    Br J Cancer; 1979 Sep 01; 40(3):335-53. PubMed ID: 508562
    [Abstract] [Full Text] [Related]

  • 39. Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs.
    White RA, Workman P.
    Br J Cancer; 1980 Feb 01; 41(2):268-76. PubMed ID: 7370166
    [Abstract] [Full Text] [Related]

  • 40. Distribution and tumor penetration properties of a radiosensitizer 2-[14C] misonidazole (Ro 07-0582), in mice and rats as studied by whole-body autoradiography.
    Akel G, Benard P, Canal P, Soula G.
    Cancer Chemother Pharmacol; 1986 Feb 01; 17(2):121-6. PubMed ID: 3719893
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.